Document:

<PAGE>

                                                                    EXHIBIT 10.3

                          AMENDMENT NUMBER TWO TO THE
                                  AVIALL, INC.
                 AMENDED AND RESTATED 1998 DIRECTORS STOCK PLAN

     THIS AMENDMENT TO THE AVIALL, INC. AMENDED AND RESTATED 1998 DIRECTORS
STOCK PLAN (this "Amendment"), dated as of June 26, 2003, is made and entered
into by Aviall, Inc., a Delaware corporation (the "Company"). Terms used in this
Amendment with initial capital letters that are not otherwise defined herein
shall have the meanings ascribed to such terms in the Aviall, Inc. Amended and
Restated 1998 Directors Stock Plan (the "Plan").

                                    RECITALS

     WHEREAS, Section XI of the Plan provides that the Board of Directors of the
Company (the "Board") may amend the Plan and the Board desires to obtain
stockholder approval of the proposal to amend the Plan; and

     WHEREAS, the Board submitted the proposal to amend the Plan to the
Company's stockholders at the 2003 Annual Meeting of Stockholders; and

     WHEREAS, the Company's stockholders approved the proposal to amend the
Plan;

     NOW, THEREFORE, in accordance with Section XI of the Plan, the Company
hereby amends the Plan as follows:

1. Paragraph C of Section IV of the Plan is hereby amended, effective as of
January 1, 2004, by deleting the first sentence of said paragraph in its
entirety and substituting in lieu thereof the following:

          C. Stock Grants--Each participating Director who has made an election
     to participate in the Plan pursuant to Paragraph B of this Section IV shall
     be eligible to receive annually, on the first New York Stock Exchange
     trading day in February of each calendar year (the "Grant Date"), following
     such election, in lieu of such Director's annual retainer for service as a
     director of the Company (the "Annual Retainer") a grant of Common Stock.

2. Paragraph A of Section V of the Plan is hereby amended, effective as of
January 1, 2004, by deleting said paragraph in its entirety and substituting in
lieu thereof the following:

          A. Vesting--With respect to grants of Common Stock made prior to
     January 1, 2004, each grant of Common Stock made to a participating
     Director in accordance with Section IV shall be vested on the six-month
     anniversary of the Grant Date, so long as the Director has served
     continuously as a director of the Company during the intervening six-month
     period; provided, however, that a participating Director who leaves the
     Board of Directors of the Company following the completion of the term of
     service for which the Director was elected prior to the end of such
     six-month period or whose service during such six-month period was
     interrupted due to death or disability shall be vested in a pro rata number
     of such shares. With respect to grants of Common Stock made on or after
     January 1, 2004, each grant of Common Stock to a participating Director in
     accordance with Section IV shall be vested on the eleven-month anniversary
     of the Grant Date, so long as the Director has served continuously as a
     director of the Company during the intervening eleven-month period;
     provided, however, that a participating Director who leaves the Board of
     Directors of the Company following the

<PAGE>

     completion of the term of service for which the Director was elected prior
     to the end of such eleven-month period or whose service during such
     eleven-month period was interrupted due to death or disability shall be
     vested in a pro rata number of such shares. Except as described in the
     preceding sentence, in the event a Director's service to the Company
     terminates before the shares have vested, then all shares granted to such
     Director which have not vested shall be canceled and such shares shall be
     forfeited and retransferred to the Company, with the Director having no
     further right or interest in such forfeited and retransferred shares.

3. Paragraph A of Section VI of the Plan is hereby amended, effective June 26,
2003 by deleting said Paragraph in its entirety and substituting in lieu thereof
the following:

          A. The Board may, from time to time and upon such terms and conditions
     as it may determine, authorize the granting to an Eligible Director of
     rights to purchase shares of Common Stock upon the exercise of an option
     granted pursuant to this Section VI ("Option Rights"). Notwithstanding
     anything in this Section VI or elsewhere in this Plan to the contrary and
     subject to adjustment as provided in Section IX, no Director shall be
     granted Option Rights for more than 5,000 shares of Common Stock during any
     fiscal year of the Company.

4. Subparagraph (ii) in Paragraph B of Section VI of the Plan is hereby amended,
effective as of January 1, 2004, by deleting said subparagraph in its entirety
and substituting in lieu thereof the following:

          (ii) With respect to grants of Common Stock made prior to January 1,
     2004, each such Option Right shall become exercisable in full on such date
     or dates not less than six months nor more than five years from the Grant
     Date, so long as the Director has served continuously as a director of the
     Company during the intervening period, and shall become exercisable in full
     immediately in the event of a Change in Control, as defined in Section VII.
     With respect to grants of Common Stock made on or after January 1, 2004,
     each such Option Right shall become exercisable in full on such date or
     dates not less than eleven months nor more than five years from the Grant
     Date, so long as the Director has served continuously as a director of the
     Company during the intervening period, and shall become exercisable in full
     immediately in the event of a Change in Control, as defined in Section VII.

5. Subparagraph (iii) in Paragraph B of Section VI of the Plan is hereby
amended, effective as of January 1, 2004, by deleting said subparagraph in its
entirety and substituting in lieu thereof the following:

          (iii) With respect to grants of Common Stock made prior to January 1,
     2004, in the event of the termination of service on the Board by the holder
     of any such Option Rights other than by reason of disability or death, the
     then outstanding Option Rights of such holder may be exercised to the
     extent that they would be exercisable on the date that is six months and
     one day after the date of such termination and shall expire eleven months
     and one day after such termination, or on their stated expiration date,
     whichever occurs first. With respect to grants of Common Stock made on or
     after to January 1, 2004, in the event of the termination of service on the
     Board by the holder of any such Option Rights other than by reason of
     disability or death, the then outstanding Option Rights of such holder may
     be exercised to the extent that they would be exercisable on the date that
     is eleven months and one day after the date of such termination and shall

<PAGE>

     expire eleven months and one day after such termination, or on their stated
     expiration date, whichever occurs first.

6. Except as expressly amended by this Amendment and Amendment No. One to the
Aviall, Inc. Amended and Restated 1998 Directors Stock Plan dated June 14, 2002,
the Plan shall continue in full force and effect in accordance with the
provisions thereof.

IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as
of the date first written above.

                                      AVIALL, INC.

                                         By: /s/ Jeffrey J. Murphy
                                             ----------------------
                                         Name: Jeffrey J. Murphy
                                         Title: Senior Vice President, Law &
                                                 Human Resources, Secretary and
                                                 General Counsel<PAGE>
                                                                   EXHIBIT 4.3.2

                                SECOND SUPPLEMENT
                              TO NOMINEE AGREEMENT

         This SECOND SUPPLEMENT TO NOMINEE AGREEMENT, executed and delivered
this ______ day of June, 2003 (this "Second Supplement"), by and between CENTEX
CORPORATION, a Nevada corporation ("Centex"), 3333 HOLDING CORPORATION, a Nevada
corporation ("Holding"), CENTEX DEVELOPMENT COMPANY, L.P., a Delaware limited
partnership ("CDC"), of which 3333 Development Corporation, a Nevada corporation
that is a wholly-owned subsidiary of Holding, is the sole general partner, and
MELLON INVESTOR SERVICES LLC ("Mellon") f/k/a CHASEMELLON SHAREHOLDER SERVICES
L.L.C., a New Jersey limited liability company.

         WITNESSETH:

         WHEREAS, Centex, Holding, CDC and First RepublicBank Dallas, National
Association ("First RepublicBank") entered into a Nominee Agreement as of
November 30, 1987 (the "Nominee Agreement"), pursuant to which Centex effected a
distribution to First RepublicBank, for the benefit of those persons who are
from time to time holders of the common stock of Centex, of certain securities,
as more fully described therein; and

         WHEREAS, Centex, Holding, CDC, ChaseMellon Shareholder Services L.L.C.
("ChaseMellon") and The Chase Manhattan Bank ("Chase") entered into a Supplement
to Nominee Agreement as of July 27, 2000 (the "First Supplement"), pursuant to
which Chase was appointed as successor Nominee under the Nominee Agreement,
ChaseMellon was appointed as successor Transfer Agent under the Nominee
Agreement, and the termination date of the Nominee Agreement was extended from
November 30, 1997 to November 30, 2007, as more fully described therein; and

         WHEREAS, Chase has tendered its resignation as successor Nominee and
Centex desires to appoint a replacement; and

         WHEREAS, ChaseMellon has changed its corporate name to Mellon Investor
Services LLC and is continuing in its appointment as successor Transfer Agent;
and

         WHEREAS, the parties hereto are executing this Second Supplement to
formally recognize the appointment of a successor Nominee and to acknowledge the
successor Transfer Agent's change of name to clarify the rights and obligations
of the parties hereto and the respective parties to the Nominee Agreement.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants set forth herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, Centex, Holding, CDC
and Mellon do hereby agree as follows:

         1. Definitions.

            a) Except as expressly defined otherwise in this Second Supplement,
capitalized terms used and otherwise defined herein shall have the respective
meanings assigned to them in the Nominee Agreement.

<PAGE>

            b) The following defined terms in the Nominee Agreement are hereby
amended:

         "Corporate Office" means (a) as to the Nominee, the corporate office
          of the Nominee, located at c/o Mellon Investor Services LLC, 600
          North Pearl Street, Dallas, Texas 75201, and (b) as to the Transfer
          Agent, the principal corporate office of the Transfer Agent, which
          at the date hereof is located at 85 Challenger Road, Ridgefield
          Park, New Jersey 07660.

         2. Appointment of Successor Nominee. Centex hereby accepts the
resignation of Chase as Nominee and appoints Mellon Investor Services LLC
("Mellon") as Successor Nominee pursuant to Section 8.1 of the Nominee
Agreement. Mellon hereby accepts such appointment for all purposes. Each
reference in the Nominee Agreement to the Nominee or to the Bank (each as
defined in the Nominee Agreement), in its capacity as Nominee, shall be deemed
after the effective date of this Second Supplement to be a reference to Mellon,
unless the context otherwise plainly requires.

         3. Appointment of Successor Transfer Agent in the First Supplement. In
the First Supplement, Centex appointed ChaseMellon as successor Transfer Agent
pursuant to Section 8.1 of the Nominee Agreement, and ChaseMellon accepted such
appointment. ChaseMellon Shareholder Services, L.L.C. has since changed its name
to Mellon Investor Services LLC. Accordingly, each reference in the Nominee
Agreement to the Transfer Agent or the Bank (each as defined in the Nominee
Agreement), in its capacity as Transfer Agent, shall be deemed after the
effective date of this Second Supplement to be a reference to Mellon, unless the
context otherwise plainly requires.

         4. Addresses for Notices. The addresses listed in Section 9.4(a) of the
Nominee Agreement are hereby replaced with the following:

                  To Centex or Holding, at

                  2728 North Harwood Street
                  Dallas, Texas 75201
                  Attention:  President

                  To CDC, at:

                  Centex Development Company, L.P.
                  c/o 3333 Development Corporation
                  2728 North Harwood Street
                  Dallas, Texas 75201
                  Attention:  President

                  To the Nominee, at:

                  c/o Mellon Investor Services LLC
                  600 North Pearl, Suite 1010
                  Dallas, Texas 75201
                  Attention:  Centex Relationship Manager

<PAGE>

                  To the Transfer Agent, at:

                  c/o Mellon Investor Services LLC
                  600 North Pearl, Suite 1010
                  Dallas, Texas 75201
                  Attention:  Centex Relationship Manager

         5. Fees. The fees for services provided by Mellon in its capacity as
Nominee are set forth in the Fee Schedule attached hereto as Exhibit A. The fees
for services provided by Mellon in its capacity as Transfer Agent shall be in
accordance with the Service Agreement for Transfer Services then in effect
between Centex, Holding, CDC and Mellon.

         Except as otherwise expressly contemplated or amended by this Second
Supplement, the terms and provisions of the Nominee Agreement and the First
Supplement shall continue in full force and effect.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

<PAGE>

         IN WITNESS WHEREOF, Centex, Holding, CDC, and Mellon have duly executed
this Second Supplement as of the day and year first set forth above.

                             CENTEX CORPORATION

                             By:
                                -----------------------------------------------
                                Name:   Raymond G. Smerge
                                Title:  Executive Vice President

                             3333 HOLDING CORPORATION

                             By:
                                -----------------------------------------------
                                Name:   Stephen M. Weinberg
                                Title:  President and Chief Executive Officer

                             CENTEX DEVELOPMENT COMPANY, L.P.

                             By: 3333 DEVELOPMENT CORPORATION,
                                  General Partner

                                  By:
                                     ------------------------------------------
                                     Name: Stephen M. Weinberg
                                     Title:President and Chief Executive Officer

                             MELLON INVESTOR SERVICES LLC

                             By:
                                -----------------------------------------------
                                Name:  David M. Cary
                                Title: Vice President

<PAGE>

                                    EXHIBIT A

<Table>
<S>                                                                        <C>
Initial Set-up Fee
                                                                           $2,500.00

Annual Administration and Safekeeping of Deposited Securities
under Section 2.1 of the Nominee Agreement                                 $2,500.00
</Table>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]